Lunai Bioworks Achieves Complete Regression of Pancreatic Tumors in Preclinical Models

Reuters11-05

<a href="https://laohu8.com/S/LNAI">Lunai Bioworks</a> Achieves Complete Regression of Pancreatic Tumors in Preclinical Models

Lunai Bioworks Inc. has announced a major scientific breakthrough in cancer immunotherapy, reporting that its next-generation allogeneic dendritic cell $(DC)$ therapy led to complete regression of both primary and metastatic pancreatic tumors in preclinical humanized mouse models. The results have already been published in the peer-reviewed journal "Vaccines" on November 2, 2025. The study details the development of a second-generation, clinical-grade DC construct, genetically engineered to activate the immune system against cancer. This advancement represents a significant step toward clinical trials and positions Lunai Bioworks at the forefront of next-generation cell-based immunotherapies for pancreatic cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA16441) on November 05, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581477523?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 22:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581477523","market":"fut","top_or_hot":-1,"title":"Lunai Bioworks Achieves Complete Regression of Pancreatic Tumors in Preclinical Models","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/LNAI\">Lunai Bioworks</a> Achieves Complete Regression of Pancreatic Tumors in Preclinical Models\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/RENB\">Lunai Bioworks</a> Inc. has announced a major scientific breakthrough in cancer immunotherapy, reporting that its next-generation allogeneic dendritic cell <a href=\"https://laohu8.com/S/DC\">$(DC)$</a> therapy led to complete regression of both primary and metastatic pancreatic tumors in preclinical humanized mouse models. The results have already been published in the peer-reviewed journal \"Vaccines\" on November 2, 2025. The study details the development of a second-generation, clinical-grade DC construct, genetically engineered to activate the immune system against cancer. This advancement represents a significant step toward clinical trials and positions Lunai Bioworks at the forefront of next-generation cell-based immunotherapies for pancreatic cancer.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA16441) on November 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lunai Bioworks Achieves Complete Regression of Pancreatic Tumors in Preclinical Models</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLunai Bioworks Achieves Complete Regression of Pancreatic Tumors in Preclinical Models\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-05 22:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/LNAI\">Lunai Bioworks</a> Achieves Complete Regression of Pancreatic Tumors in Preclinical Models\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/RENB\">Lunai Bioworks</a> Inc. has announced a major scientific breakthrough in cancer immunotherapy, reporting that its next-generation allogeneic dendritic cell <a href=\"https://laohu8.com/S/DC\">$(DC)$</a> therapy led to complete regression of both primary and metastatic pancreatic tumors in preclinical humanized mouse models. The results have already been published in the peer-reviewed journal \"Vaccines\" on November 2, 2025. The study details the development of a second-generation, clinical-grade DC construct, genetically engineered to activate the immune system against cancer. This advancement represents a significant step toward clinical trials and positions Lunai Bioworks at the forefront of next-generation cell-based immunotherapies for pancreatic cancer.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA16441) on November 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LNAI","symbol_name":"Lunai Bioworks","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDLbWrr86:1","article_id":"2581477523","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581477523","pubTimestamp":1762352583,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Lunai Bioworks Inc. has announced a major scientific breakthrough in cancer immunotherapy, reporting that its next-generation allogeneic dendritic cell  therapy led to complete regression of both primary and metastatic pancreatic tumors in preclinical humanized mouse models. The results have already been published in the peer-reviewed journal \"Vaccines\" on November 2, 2025. The study details the development of a second-generation, clinical-grade DC construct, genetically engineered to activate the immune system against cancer. This advancement represents a significant step toward clinical trials and positions Lunai Bioworks at the forefront of next-generation cell-based immunotherapies for pancreatic cancer.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investmen","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LNAI":"Lunai Bioworks","BK4139":"生物科技"},"translate_title":"Lunai Bioworks在临床前模型中实现胰腺肿瘤的完全消退","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LNAI":0.9},"content_text":"Lunai Bioworks Achieves Complete Regression of Pancreatic Tumors in Preclinical Models\n    \n\nLunai Bioworks Inc. has announced a major scientific breakthrough in cancer immunotherapy, reporting that its next-generation allogeneic dendritic cell $(DC)$ therapy led to complete regression of both primary and metastatic pancreatic tumors in preclinical humanized mouse models. The results have already been published in the peer-reviewed journal \"Vaccines\" on November 2, 2025. The study details the development of a second-generation, clinical-grade DC construct, genetically engineered to activate the immune system against cancer. This advancement represents a significant step toward clinical trials and positions Lunai Bioworks at the forefront of next-generation cell-based immunotherapies for pancreatic cancer.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA16441) on November 05, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581477523","isCrawlerRequest":true}